Sunflower Therapeutics
CAMBRIDGE, MA · Biotechnology · 21 employees
Sunflower Therapeutics is a unique biotech with a mission to transform bioeconomies worldwide by creating accessible solutions for protein product development and commercial manufacturing. Using our core technologies – an efficient host, data-driven methods for process development, and continuous biomanufacturing equipment – our team aims to democratize bioprocessing.
Funding history
- Funding Round — $2.4M — Sep 2025
- Series seed — $2.0M — May 2024
- Series seed — $610K — Oct 2022
Recent signals
- Sep 18, 2025: Sunflower Therapeutics Collaborates with SK bioscience on Cost-Effective HPV Vaccine and Receives First Milestone Payment.
- Sep 03, 2025: Raised $2.4M
- Feb 26, 2025: Launched Sunflower Therapeutics has launched the Daisy Petal™ Perfusion Bioreactor System through a distribution agreement with PharmNXT Biotech.
- Dec 03, 2024: Sunflower Therapeutics Closes $3M Agreement for Future Equity (SAFE) with Oversubscription
- Jul 25, 2024: SK bioscience Invests $2M in Sunflower Therapeutics for Research and Development Collaborations
- May 24, 2024: Raised $2.0M in Series seed
- Oct 14, 2022: Raised $610K in Series seed
See plans & pricing → Track Sunflower Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.